{"analyses":[{"ciLowerLimit":"0.79","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.15","estimateComment":"Reference level = TAS x 8 weeks","groupDescription":"With 1540 patients accrued over 4 years and observed for an additional 6 years, determined for the primary endpoint, there would be 90% power to detect a 22% reduction in the hazard of all cause deaths in the 28-week arm, with 2-sided significance level of 0.05. This sample accounted for a 10% ineligible/lack-of-data rate.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.62","paramType":"Hazard Ratio (HR)","paramValue":"0.95","statisticalComment":"2-sided significance level of 0.05","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"62","upperLimit":"70","value":"66"},{"groupId":"OG001","lowerLimit":"63","upperLimit":"71","value":"67"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"752"},{"groupId":"OG001","value":"737"}],"units":"Participants"}],"description":"Survival time is defined as time from randomization to the date of death from any cause and is estimated by the Kaplan-Meier method. Patients last known to be alive are censored at the date of last contact. Ten-year rate is reported.","dispersionType":"95% Confidence Interval","groups":[{"description":"Total Androgen Suppression (TAS) (LHRH agonist and Casodex or Eulexin) x 8 weeks followed by radiation therapy (RT) with concurrent TAS (LHRH agonist and Casodex or Eulexin).","id":"OG000","title":"TAS x 8 Weeks"},{"description":"TAS (LHRH agonist and Casodex or Eulexin) x 28 weeks followed by RT with concurrent TAS (LHRH agonist and Casodex or Eulexin).","id":"OG001","title":"TAS x 28 Weeks"}],"paramType":"NUMBER","populationDescription":"Eligible patients with follow-up data","reportingStatus":"POSTED","timeFrame":"From randomization to 10 years. (Patients are followed until death or study termination, whichever occurs first.)","title":"Overall Survival (OS) (10-year Rates Reported)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}